Sei Investments Co. Has $322,000 Stake in Amedisys, Inc. (NASDAQ:AMED)

Sei Investments Co. reduced its stake in Amedisys, Inc. (NASDAQ:AMED) by 50.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,549 shares of the health services provider’s stock after selling 3,636 shares during the period. Sei Investments Co.’s holdings in Amedisys were worth $322,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. National Bank of Canada FI boosted its position in Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after buying an additional 30,213 shares in the last quarter. ABC Arbitrage SA acquired a new stake in shares of Amedisys during the 4th quarter valued at $2,522,000. Geode Capital Management LLC grew its position in Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after acquiring an additional 7,071 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new position in Amedisys in the 3rd quarter worth about $7,238,000. Finally, Empowered Funds LLC bought a new position in Amedisys in the fourth quarter valued at about $318,000. 94.36% of the stock is owned by institutional investors.

Amedisys Stock Performance

Shares of Amedisys stock opened at $91.50 on Friday. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of 36.31, a P/E/G ratio of 1.78 and a beta of 0.89. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The company’s fifty day moving average is $92.22 and its 200 day moving average is $92.09.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Sell-side analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens reaffirmed an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $101.00.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.